Clinical trial
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose…
NCT00248144 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00248144 |
|---|---|
| Title | A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis |
| Official title | A Randomized, Multicenter, Double-Blinded Controlled Study to Compare the Effectiveness of a Single Dose (1500 mg) of Famciclovir, One Day (750 mg q12) of Famciclovir and Placebo in Patient-Initiated Episodic Treatment of Recurrent Herpes Labialis |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Recurrent Herpes Labialis |
| Intervention type | Drug |
| Interventions | Famciclovir |
| Start date | Oct 1, 2003 |
| Completion | Jul 1, 2007 |
| First posted | Nov 3, 2005 |
| Last update posted | Dec 10, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: